NORTH CHICAGO, Ill., Nov. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the 20 recipients of its second annual AbbVie Migraine Career Catalyst Award™ contest, an initiative that helps people living with migraine pursue their career and professional development goals. Each winner received $2,500 in financial support to invest in opportunities that advance their aspirations, from continued education and training to creating healthier, more supportive work environments.
Migraine affects one in six people and is present in nearly every workplace. Still, despite its widespread impact and significant costs, awareness and understanding remain limited. Amid these challenges, many people living with migraine continue to redefine what is possible, showing remarkable resilience and advocacy in both their personal and professional lives.
The contest drew entries from across the United States, with winners representing a broad mix of professions and life stages. Despite the challenges that migraine often presents, each recipient shared a powerful story of resilience, ambition, and commitment to advancing their professional goals. Among the 20 awardees, several shared reflections on what the recognition means to them and how it will help shape their professional paths:
Many people with migraine continue to face stigma, bias and insufficient support in their professional lives.2 The AbbVie Migraine Career Catalyst Award contest was created to help close this gap, providing recognition, resources, and visibility for individuals whose careers have been disrupted by migraine. By supporting their goals, AbbVie is helping to foster greater understanding of the realities of living and working with migraine.
"AbbVie is helping shift how workplaces and society understand migraine, while empowering individuals to thrive and pursue their goals," said Jag Dosanjh, senior vice president, AbbVie, and president, neuroscience and eye care. "We recognize that migraine doesn't just interrupt workdays, it can alter career trajectories. We're proud to be the only company to offer three treatment options that address the spectrum of migraine and we are continuing to research and drive innovation to uncover new therapies that can help people living with this debilitating disease."
For the complete list of 2025 winners, visit www.migrainecareercatalyst.com.
About AbbVie in Migraine
AbbVie is the only company with three prescription treatments designed to meet patient needs across the full spectrum of migraine to help patients living with this debilitating disease. However, our commitment to the community goes beyond medicine. Through our research and partnerships with the migraine community – including patients, healthcare providers, and advocacy organizations – AbbVie has a deep understanding of the challenges that people living with migraine can face in the workplace. The AbbVie Migraine Career Catalyst Award contest is an extension of this commitment, empowering people living with migraine to pursue their professional objectives.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – as well as products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Media Contact:
Jacqueline Karis
+1 (310) 486-4993
This email address is being protected from spambots. You need JavaScript enabled to view it.
References:
US-NEUM-250114 11/25

| Last Trade: | US$232.36 |
| Daily Change: | 0.07 0.03 |
| Daily Volume: | 5,054,474 |
| Market Cap: | US$411.280B |
October 31, 2025 October 30, 2025 October 29, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load